Furthermore, advances in classification of many cancer promoting genes and miRNA signatures for uncovering the biological mechanism of oncogenic TMPRSS2-ERG fusions associated genomic changes have been summarized, along with the drug targets and biomarkers for prostate cancer development. The gene discussed is TMPRSS2; the disease is cancer.